Hanmi Science, the holding company of Hanmi Pharm, announced a significant restructuring, welcoming OCI Group as its major shareholder and establishing a joint management system.
The move, made public on Saturday last week, was a surprise to many, including Hanmi Pharm CEO Lim Jong-yoon, who expressed regret and confusion over the decision.
The restructuring involves a stock swap between Hanmi Science and OCI Holdings, the holding company of OCI Group. This decision, unanimously agreed upon by the board members of Hanmi Science, was not communicated to Lim, …
Read the full article at: https://www.koreabiomed.com/news/articleView.html?idxno=23065